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Abstract
Background:  L-arginine is the common substrate for nitric oxide synthases and arginases.
Increased arginase levels in the blood of patients with cystic fibrosis may result in L-arginine
deficiency and thereby contribute to low airway nitric oxide formation and impaired pulmonary
function.
Methods: Plasma amino acid and arginase levels were studied in ten patients with cystic fibrosis
before and after 14 days of antibiotic treatment for pulmonary exacerbation. Patients were
compared to ten healthy non-smoking controls.
Results: Systemic arginase levels measured by ELISA were significantly increased in cystic fibrosis
with exacerbation compared to controls (17.3 ± 12.0 vs. 4.3 ± 3.4 ng/ml, p < 0.02). Arginase levels
normalized with antibiotic treatment. Plasma L-arginine was significantly reduced before (p < 0.05)
but not after treatment. In contrast, L-ornithine, proline, and glutamic acid, all downstream
products of arginase activity, were normal before, but significantly increased after antibiotic
therapy. Bioavailability of L-arginine was significantly reduced in cystic fibrosis before and after
exacerbation (p < 0.05, respectively).
Conclusion: These observations provide further evidence for a disturbed balance between the L-
arginine metabolic pathways in cystic fibrosis.
Background
Nitric oxide (NO) is a messenger molecule that is
involved in a variety of biological and physiological proc-
esses in the lung. Constitutive endogenous formation of
NO in airways is thought to play a role in neurotransmis-
sion, smooth muscle relaxation and bronchodilation. [1]
Airway NO formation by NO synthases (NOSs) can be
increased in response to inflammatory mediators pre-
dominantly through induction of the calcium-independ-
ent isoform NOS2. [1] Despite the inflammatory nature
of lung disease in cystic fibrosis (CF), fractional exhaled
NO (FENO), as well as concentrations of the bioactive NO-
metabolites S-nitrosothiols (SNOs) in airway fluids are
decreased in CF patients. [2-4] While the reasons for
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impaired NO formation remain incompletely under-
stood, there is accumulating evidence that low airway NO
contributes to lung pathophysiology in CF. [5-9]
Enzymatic NO formation from NOSs requires the semi-
essential amino acid L-arginine as substrate. L-arginine is
also metabolized by an enzyme of the urea cycle named
arginase which exists in type I and type II isoforms. While
arginase II is located mitochondrial, arginase I is a cyto-
plasmatic enzyme. Arginase can limit NO formation
through increased consumption of the common sub-
strate. [10-12] It was recently shown that arginase activity
is increased in sputum of patients with CF. [9] Evidence
for increased systemic arginase activity in CF came from a
study showing that oral supplementation of L-arginine in
a single dose of 200 mg/kg body weight resulted in a sig-
nificantly higher increase of L-ornithine, the product of
arginase activity, in plasma of CF patients compared to
healthy controls. [13] These data suggest that the con-
sumption of L-arginine by arginase could be increased in
CF, possibly resulting in reduced availability of L-arginine
for NO synthesis. To address this question, we measured
plasma amino acid levels and arginase concentrations in
patients with CF before and after antibiotic treatment for
pulmonary exacerbations.
Methods
Study cohort and protocol
10 CF patients (3 females) aged 16 to 39 years with a
mean (± SD) age of 21.9 (± 6.2) years were included in
this study. The diagnosis of CF had been confirmed in all
patients by repeated sweat tests with chloride concentra-
tions exceeding 60 mmol/L and by CFTR gene mutation
analysis. Exclusion criteria were g-tube feeding, allergic
bronchopulmonary aspergillosis or B. cepacia infection.
Patients studied were admitted to hospital for intravenous
antibiotic treatment of a pulmonary exacerbation. Blood
was drawn into two 2.7 ml EDTA containing tubes for
plasma amino acid (n = 10) and arginase (n = 7) measure-
ments on the morning after admission and after 14 days
of antibiotic treatment under fasting conditions in the
morning prior to breakfast, respectively. Pulmonary func-
tion tests by spirometry were performed on the same day
in each patient but one, who was unable to perform
spirometry. Mean forced vital capacity (FVC) at admission
was 54.1 (± 22.7) % and FEV1 was 32.4 (± 10.6) % of pre-
dicted values, respectively. Mean BMI of the patients was
18.5 (± 2.2). Sputum microbiology revealed P. aeruginosa
in 8 patients, Acinetobacter baumanii in 1 and Stenotropho-
monas  plus  Staph. aureus in one patient. Patients were
treated with ceftazidime (n = 5) or meropenem (n = 5)
plus an aminoglycoside respectively. One patient received
oral steroids on three days during treatment, two addi-
tional patients were on long term treatment with inhaled
budesonide.
Patients were compared to 10 (3 females) non-smoking,
healthy controls that were 23 to 28 years (24.4 ± 2.1 years)
of age. In controls blood was also drawn into two 2.7 ml
EDTA containing tubes in the morning under fasting con-
ditions. Written informed consent was obtained from
each CF patient, and/or their parents, and all healthy con-
trols, respectively. The study was approved by the institu-
tional review board of the University of Duisburg-Essen.
Plasma amino acids measurements
Amino acids were determined by ion exchange chroma-
tography on an amino acid analyzer LC 3000 (Eppendorf,
Hamburg, Germany) according to the manufacturer's
specifications. Plasma samples were deproteinized within
30 minutes after collection.
Arginase ELISA
Plasma levels of arginase I (liver type) were measured
using a commercially available enzyme-linked immono-
sorbent assay (ELISA) kit (BioVendor Laboratory Medi-
cine, Inc. Brno, Czech Republic). Plasma samples for the
arginase ELISA were centrifuged at 1000 g for 10 min
immediately after they were obtained. Clear supernatant
was kept at -80C before analyzed.
Statistics
Data were expressed as mean ± standard deviation (SD).
Kolmogorov-Smirnov test revealed normal distribution of
all values in the groups. Comparisons within groups (pre
vs. post treatment) were therefore made by paired t-test
and inter-group comparisons were done by unpaired t-
test. A p value below 0.05 was considered statistically sig-
nificant. PC-Statistik v2.11 (TopSoft Hannover, Germany)
was used for statistical analysis.
Results
Amino acid levels
Significantly reduced plasma concentrations were found
for 9 out of 20 amino acids tested in CF patients admitted
with pulmonary exacerbations. With the exception of his-
tidine none of the amino acid levels were subnormal after
14 days of antibiotic therapy. Glycine as well as the down-
stream products of arginase activity, i.e. L-ornithine, pro-
line, and glutamic acid were not reduced at admission but
were significantly increased after antibiotic therapy when
compared to controls, respectively (Table 1) (Figure 1).
L-arginine plasma concentrations were decreased in CF
patients with an exacerbation when compared to controls,
with three patients having values of 13.6 μM, 21.2 μM,
and 35.1 μM respectively, which is below published refer-
ence values (36–139 μM). [14] Plasma L-arginine signifi-
cantly increased to normal values in CF during antibiotic
therapy (Figure 1). The rate limiting factor for cellular
uptake of L-arginine is the CAT transporter, which alsoRespiratory Research 2006, 7:87 http://respiratory-research.com/content/7/1/87
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transports L-ornithine and lysine. [15] The ratios of L-
arginine/L-ornithine, as well L-arginine/L-ornithine +
lysine, therefore, provide indices of relative L-arginine
availability at any given plasma L-arginine concentration.
Both these ratios were significantly reduced in the CF
patients before and after treatment for pulmonary exacer-
bation (Figure 2).
Arginase concentrations
Plasma arginase concentrations in healthy controls were
4.3 ± 3.4 ng/ml. Arginase levels were significantly
increased in CF patients with pulmonary exacerbation
(17.3 ± 12.0 ng/ml, p < 0.02) and returned to normal val-
ues after 14 days of antibiotic therapy (2.4 ± 2.3 ng/ml)
(Figure 3).
Discussion
In this study we found evidence for reduced systemic
availability of L-arginine, the substrate for NOS, in CF
patients. While increased arginase I and decreased L-
arginine concentrations in plasma at the time of pulmo-
nary exacerbation normalized with antibiotic treatment,
the relative bioavailability of L-arginine remained signifi-
cantly reduced in CF patients. This was associated with an
amino acid profile consistent with increased arginase
activity even after treatment for pulmonary exacerbation.
L-arginine is a semi-essential amino acid that is found in
many comestible goods but can also be biosynthesized
from citrulline (by argininosuccinate synthase and
argininosuccinate lyase, the third and fourth enzymes of
Plasma amino acids Figure 1
Plasma amino acids. Plasma concentrations of L-arginine (A), L-ornithine (B), proline (C), and glutamic acid (D) in cystic 
fibrosis patients (CF) before (baseline) and after 14 days of antibiotic treatment as well as controls. Results are plotted as 
means ± SD. Asterisk indicates significant (p < 0.05) difference to controls.
A           B  
baseline 14 days controls
0
25
50
75
100
*
L
-
a
r
g
i
n
i
n
e
 
(
μ
μ
μ
μ
M
)
CF baseline CF 14days controls
0
25
50
75
100
*
L
-
o
r
n
i
t
h
i
n
e
 
(
μ
μ
μ
μ
M
)
    C          D
CF baseline CF 14days controls
0
100
200
300 *
P
r
o
l
i
n
e
(
μ
μ
μ
μ
M
)
CF baseline CF 14days controls
0
30
60
90
120 * *
G
l
u
t
a
m
i
c
 
a
c
i
d
 
(
μ
μ
μ
μ
M
)Respiratory Research 2006, 7:87 http://respiratory-research.com/content/7/1/87
Page 4 of 7
(page number not for citation purposes)
the urea cycle). L-arginine is essential for protein synthesis
and a substrate for urea, polyamines, proline, L-
glutamine, creatinine phospate, agmatine as well as enzy-
matic NO formation. Arginine is transported from blood
into cells by cationic amino acid transporter (CAT) iso-
forms. The availability of L-arginine is one of the rate-lim-
iting factors in cellular NO production. [10,12] Therefore,
L-arginine deficiency may, at least in part, account for the
reduced NO formation seen in the CF airways.
A lack of NO formation is of relevance for CF pathophys-
iology since there is increasing evidence that decreased
NO formation has a negative effect on defense against
bacterial infections, and contributes to airway obstruction
in CF. [2,5,7,9,16-18] However, most actions of NOSs
seem to be mediated by S-nitrosylated proteins and not by
NO itself [19]. Depletion of S-nitrosothiols (SNOs) is
thought to aggravate airway obstruction [20-22], and
SNO levels were found to be decreased in CF airways [3].
Furthermore, SNOs have been shown to increase expres-
sion, maturation and function of both wild-type and Δ
F508 CFTR. [23-25] Of interest, cysteine, which contains
a thiol group, is the rate limiting amino acid in the synthe-
sis of glutathione (GSH), [26] an antioxidant which con-
tributes to the redox imbalance in CF. The low cysteine
plasma concentrations seen in the CF patients studied
here, may therefore not only contribute to low SNOs but
also reduced GSH formation and consequently GSNO
deficiency in CF.
Low L-arginine concentrations may, however, not only
result in decreased NO or SNO formation but also in
increased reactive oxygen nitrogen species that contribute
to tissue damage. Although superoxide generation from
NOS3 appears to be regulated by BH4 rather than L-
arginine, [27] it is known that calmodulin-bound NOS
can release reactive oxygen species such as superoxide and
H2O2 at non-saturating L-arginine levels, [28,29] and that
NOS can generate NO and superoxide at the same time at
low-saturating L-arginine levels. [30,31] These products
may react to generate peroxynitrite, and subsequently
result in tyrosine nitration. In fact, nitrotyrosine has been
found to be increased in CF lung tissue, [32] sputum, [33]
and exhaled breath condensate from CF patients. [34]
Our data suggest that L-arginine deficiency in CF patients
results from increased L-arginine consumption by argin-
ase. The product of arginase activity, L-ornithine, is a pre-
cursor for the formation of polyamines (e.g., putrescine,
spermidine, and spermine) and proline, which control
cell proliferation and collagen production, respectively.
[35] Polyamines may be particularly important in the
lung because respiratory epithelial cells have a potent
polyamine uptake system. [36] In addition, the
Table 1: Plasma amino acid levels (μM) in controls and CF patients before and after 14 days of i.v. antibiotic treatment for pulmonary 
exacerbation
CF patients (n = 10)
Controls (n = 10) before (% control) after (% control) P-value
L-arginine 67.7 ± 19.0 48.1 ± 19.9 (71) * 68.9 ± 19.5 (102) 0.02
L-ornithine 45.7 ± 13.8 56.6 ± 34.0 (124) 65.9 ± 15.5 (144)† NS
L-citrulline 27.5 ± 8.8 28.3 ± 5.5 (103) 33.4 ± 5.8 (121) NS
Threonine 128.1 ± 40.0 87.2 ± 30.7 (68) * 129.7 ± 50.4 (101) 0.01
Serine 97.7 ± 30.0 92.0 ± 26.3 (94) 92.9 ± 17.2 (95) NS
Asparagine 52.5 ± 14.5 37.3 ± 12.4 (71) * 40.0 ± 11.0 (76) NS
Glutamic Acid 18.6 ± 7.1 69.7 ± 40.7 (375) † 65.7 ± 52.5 (353)* NS
Proline 170.3 ± 31.8 165.4 ± 43.2 (97) 216.8 ± 57.5 (127)* NS
Glycine 205.1 ± 52.9 241.8 ± 100.6 (118) 323.5 ± 69.1 (158)† 0.02
Alanine 328.5 ± 73.6 243.1 ± 90.8 (74) * 355.3 ± 139.6 (108) NS
Valine 203.0 ± 25.0 169.7 ± 32.1 (84) * 176.1 ± 39.6 (87) NS
Cysteine 55.3 ± 15.6 30.1 ± 9.0 (54) † 42.4 ± 13.7 (77) 0.004
Methionine 24.9 ± 4.8 19.2 ± 5.2 (77) * 21.0 ± 5.6 (84) NS
Isoleucine 57.6 ± 10.9 52.3 ± 18.1 (91) 62.9 ± 12.9 (109) NS
Leucine 111.3 ± 22.2 90.4 ± 25.1 (81) 96.1 ± 23.9 (86) NS
Tyrosine 54.7 ± 9.8 45.7 ± 14.3 (84) 44.7 ± 11.3 (82) NS
Phenylalanine 49.9 ± 6.8 47.7 ± 10.7 (96) 49.0 ± 10.3 (98) NS
Histidine 83.7 ± 7.2 55.9 ± 17.7 (67) † 64.4 ± 17.6 (77)† NS
Tryptophan 49.8 ± 9.5 30.7 ± 15.8 (62) † 46.6 ± 11.7 (94) 0.02
Lysine 144.7 ± 42.5 144.0 ± 40.5 (100) 183.8 ± 51.9 (127) NS
Concentrations of amino acids are expressed in means ± SD. Symbols indicate significant differences of CF group to controls; *: p < 0.05, †: p ≤ 
0.01. P-values shown are for comparison between CF groups before and after antibiotic treatment.Respiratory Research 2006, 7:87 http://respiratory-research.com/content/7/1/87
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polyamine spermine has been shown to down-regulate
NO synthesis and cellular L-arginine transport by sup-
pressing the expression of NOS2 and CAT-2B in alveolar
macrophages. [37] Of interest, polyamine plasma levels
have been reported to be increased in CF in an age-
dependent manner. [38]
This is the first study to show that arginase I concentra-
tions are increased in blood of CF patients with pulmo-
nary exacerbation. Increased circulating arginase levels
may explain why mean plasma L-arginine concentrations
were decreased at this time point while arginase down-
stream products were either normal (L-ornithine and pro-
line) or increased (glutamic acid). It could also be argued
that the initial decrease of several non-related amino acids
followed by normalization during therapy may reflect an
unspecific effect such as catabolic state related to infection
or inflammation. However, the increase of L-ornithine
and proline after antibiotic therapy in the face of normal-
ized plasma L-arginine and arginase I levels provide evi-
dence that arginase activity persists in compartments of
these patients which are not reflected in measuring argin-
ase in plasma. Evidence for increased arginase activity in
clinically stable CF patients came also from a previous
study showing a higher increase in plasma L-ornithine
after a single dose of oral L-arginine in CF patients com-
pared to healthy controls. [13]
Arginase I is usually located intracellular with high con-
centrations in erythrocytes and liver cells. We could
recently demonstrate that the activity of arginase was high
in CF sputum and, although decreasing with antibiotic
treatment, remained significantly increased (approx. 10-
fold) when compared to induced sputum from healthy
controls. [9] Thus, increased plasma concentrations of
arginase down-stream products (L-ornithine, proline, and
glutamic acid) in the present of normal plasma arginase I
levels could be explained by a "spill-over effect" of these
metabolites from the CF airways into the blood stream.
This mechanism may also explain the origin of increased
plasma arginase I levels in the patients. Other sources of
arginase activity could be tissues expressing arginase II or
bacteria such as P. aeruginosa, but these were not detecta-
ble by the human arginase I ELISA used in this study.
L-arginine bioavailability Figure 2
L-arginine bioavailability. L-arginine bioavailability indices 
in CF patients before (baseline) and after 14 days of antibiotic 
treatment and in controls. Results are plotted as means ± 
SD. Asterisk indicates significant (p < 0.05) difference to con-
trols.
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Arginase I in plasma. Arginase I plasma concentrations 
measured by ELISA in CF patients before (baseline) and after 
14 days of antibiotic treatment and in controls. Results are 
plotted as means ± SD. Asterisk indicates significant (p < 
0.05) difference to controls.
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Increased systemic arginase activity and decreased L-
arginine bioavailability has recently also been found to be
involved in the pathophysiology of sickle cell disease and
asthma. [39,40]. In sickle cell disease hemolysis-related
release of erythrocyte arginase was significantly correlated
with severity of pulmonary hypertension and increased
mortality. [40] Animal experiments in a rodent model of
allergic asthma suggest that increased arginase results in
reduced L-arginine availability to constitutive NOS and
thereby contributes to airway obstruction. [41,42] In line
with these experiment, increased arginase and decreased
L-arginine bioavailability has been found in asthma
patients. [39,43] These observations suggest that L-
arginine deficiency from increased arginase activity is not
unique to CF but may play an important role in the patho-
genesis of disease conditions with increased smooth mus-
cle contractility.
Conclusion
These data provide evidence that the availability of L-
arginine is reduced in patients with CF. In addition, high
arginase concentrations in the blood in CF patients with
pulmonary exacerbation results in systemic L-arginine
deficiency and may thereby contribute to CF pathophysi-
ology.
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